Navalign, LLC Cue Biopharma, Inc. Transaction History
Navalign, LLC
- $358 Million
- Q2 2025
A detailed history of Navalign, LLC transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Navalign, LLC holds 25,000 shares of CUE stock, worth $19,750. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,000
Previous 25,000
-0.0%
Holding current value
$19,750
Previous $22,000
22.73%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding CUE
# of Institutions
48Shares Held
17.7MCall Options Held
0Put Options Held
0-
Bleichroeder LP New York, NY6.82MShares$5.39 Million1.47% of portfolio
-
Catalytic Wealth Ria, LLC Cambridge, MA3.33MShares$2.63 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.19MShares$2.52 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$597,8210.0% of portfolio
-
Geode Capital Management, LLC Boston, MA692KShares$546,8160.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $28M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...